Evommune, Inc. (EVMN) stock

EVMNNYSEPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30

$7.63−0.39 (-4.86%)

Close on Nov 13, 2026Market cap $276.91MP/E –Yield –

Evommune price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Evommune's price to sales ratio was 31.3× on Nov 11, 2026, against 2.5× a year earlier.

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	31.3×	+29.2
2025	Dec 31, 2025	2.0×	–

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is EVMN.

Revenue growth-100.0% · median 320.4%

Advertisement
300 × 250

See a number that looks wrong?